


22ND ANGLONORDIC LIFE SCIENCE CONFERENCE


COUNTY HALL, LONDON, 23 APRIL 2026

# ANGLO NORDIC



CONFERENCE BROCHURE

Tap for more

Conference organised by  **BioPartner**

# Contents

Tap an item to view

[Our Sponsors](#)



[Programme](#)



[Speakers](#)



[Charity of the Year](#)



[Technology Room Presenters: Morning](#)



[Biotech Room 1 Presenters: Morning](#)



[Biotech Room 2 Presenters: Morning](#)



[Technology Room Presenters: Afternoon](#)



[Biotech Room 1 Presenters: Afternoon](#)



[Biotech Room 2 Presenters: Afternoon](#)



[Delegations](#)



[Attending Investors](#)



[Attending Companies and Organisations](#)



# Our Sponsors

FOUNDING



CLINICAL TRIALS PANEL



1:1 PARTNERING



RECEPTION



LUNCH




DRINKS



SUPPORTING



[Back to contents](#)





## STRATEGIC, PROACTIVE AND EFFECTIVE COMMUNICATIONS FOCUSED ON OUTCOMES

Over the last 2 years our team advised on:

**67**

M&A and  
licensing deals

**\$7.3**

USD bn

**90**

Fundraisings

**\$10.8**

USD bn

**130**

Clinical  
developments

**70**


Appointments


### HELPING OUR CLIENTS RAISE FINANCE & SUPPORT DEALMAKING


For Life Sciences & Healthcare companies


- ✓ Fundraising
- ✓ Narrative development
- ✓ Deal making
- ✓ M&A
- ✓ IPO
- ✓ Crisis communications
- ✓ Profile raising
- ✓ Maximising data

Hear directly from industry leaders on **#OptimumTV** & Subscribe to Optimum's weekly **newsletter** on LinkedIn

 [optimumcomms.com](https://www.optimumcomms.com)

 [@optimumcomms](https://www.youtube.com/@optimumcomms)

 [Optimum TV](https://open.spotify.com/artist/optimumcomms)



# Programme

*Keynote and Panels will take place in Biotech Room 1*



## **MORNING PROGRAMME**

**08:00 – 08:40 Registration**

**08:40 – 08:45 Welcome**

**Mary Clark**, *CEO, Optimum Strategic Communications*

**Hakan Goker**, *Managing Director, M Ventures*

**Mattias Johansson**, *CEO, Ezenze Limited*

**08:45 – 09:10 Keynote**

**Dr. Laura Matz**, *Chief Science & Technology Officer, Merck KGaA*

**09:10 – 10:00 Panel: Ready, steady, Trial! – novel approaches for better outcomes in clinical trials**


Chair: **Charlotte Kremers**, *Principal, M Ventures*

**David Apelian** *CEO, Theolytics*

**Harel Kotler** *Clinical AI Lead, Merck Healthcare*

**Chris Floyd** *Head of Neuroscience, Transcrip*

**Orr Inbar** *Co-Founder and CEO, QuantHealth*

Sponsored by  tranScrip

**10:00-10:30 Coffee Break**

[Back to contents](#)



## 10:30 – 11:45 Pitch Presentations

Technology Room <b>Discovery Engines, AI &amp; Drug Discovery Platforms</b>	Biotech Room 1 <b>Oncology Therapeutics &amp; Precision Cancer Approaches</b>	Biotech Room 2 <b>Neuro, CNS &amp; Brain- Linked Disorders</b>
Anavo Therapeutics BV Concr Curve Therapeutics DeepLife ionSIGHT LabGenius Therapeutics Orbis Medicines	Mestag Therapeutics Moligo Technologies OncoAssign Oncoinvent ONIRIA Therapeutics Outrun Therapeutics Promatix Biosciences	CONNECTA Therapeutics FundaMental Pharma Nepsone Pharma Potentia Ltd Sania Therapeutics Serenatis Bio TauBioGenix

## 11:45 – 12:45 Investors Panel - Trends in European Life Science Investments

Chair: **Stephen Hansen**, *Director of Biopharma Intelligence, BioCentury*

**Roel Bulthuis** *Managing Partner, Syncona*

**Lucy Edwardes Jones** *Life Science Investor, BGF*


**Hakan Goker** *Managing Director, M Ventures*

**Allan Marchington** *MD and Head of Life Sciences, ICG*

**Maina Bhaman** *Partner, Sofinnova Partners*

## 12:45 - 14:00 Networking Lunch

Sponsored by **Bristows**



## AFTERNOON PROGRAMME

### 14:00 – 14:45 Panel: Partnering with Big Pharma

Chair: **Ashleigh Furlong**, *Health reporter, Bloomberg*

**Adi Hoess** *CEO, ViaNautis Bio*


**Colette Lipp** *Senior Director, Global Oncology and Immuno-Oncology  
Licensing and Business Development, Merck KGaA*

**Nicki Thompson** *CEO, TRIMTECH Therapeutics*

### 14:45 – 16:00 Pitch Presentations

Technology Room <b>Cell, Gene, RNA &amp; Advanced Delivery Modalities</b>	Biotech Room 1 <b>Immunology, Inflammation &amp; Systemic Disease</b>	Biotech Room 2 <b>Infectious Disease, Clinical Intervention &amp; MedTech</b>
Cbio CuraCell Nanoptima NanoSyrinx smartRNA StemSight ViaNautis Bio	Atrogi AB FcR Therapeutics Link Biologics Nucleome Therapeutics PharmaKrysto	AreteMedical ClotProtect Therapeutics Cytonexa iosBio MediSieve MetalloBio Synklino

### 16:00 – 16:30 Networking Break



## 16:30 – 17:20 Panel: If I Knew Then What I Know Today

Chair: **Mike Ward**, *Global Head of Life Sciences & Healthcare Thought Leadership, Clarivate*

**Olav Hellebø** *Chairman, Blue Cell Therapeutics*

**Tara Raveendran** *Head of Healthcare Research, Polar Capital*

**Marguerite Hutchinson** *Chief Business Officer, STORM Therapeutics*

**Leopoldo Zambelletti** *Independent Director*

## 17:20 – 17:25 Charity of the Year: Barts Charity

**Jay Longworth**, Director of Fundraising and Communications



## 17:25 – 17:30 Conclusions

## 17:30 – 18:45 Afternoon Drinks Reception

Hosted by

**STEPHENSON  
HARWOOD**



Bio  Partner

# BioPartner UK supported events

## SWISS BIOTECH DAY 2026

04-05 May | Basel, Switzerland

Save 1/3 with UK Delegation pass



## LSX NORDIC CONGRESS

19-20 May | Copenhagen, Denmark

10% discount available

## RESI SAN DIEGO 2026

22 Jun | San Diego, USA

\$100 discount available

## BIO INTERNATIONAL CONVENTION 2026

22-25 Jun | San Diego, USA

Save up to \$400



## **BIONOW NEUROSCIENCE CONFERENCE**

09 Jul | Sheffield, UK

**10% discount available**

---

## **NORDIC LIFE SCIENCE DAYS 2026**

08-09 Sep | Stockholm, Sweden

**15% discount available**

---

## **BIOSPAIN**

29 Sep - 01 Oct | Bilbao, Spain

**Contact us for your discount**



## **BIO-EUROPE 2026**

22-25 Jun | Cologne, Germany

**27% discount available**



With the assistance of our alliance partners, we manage the UK presence at key overseas conferences. We also recommend a number of investor conferences and internationally focused events.

**SEE ALL OF OUR  
MUST-ATTEND EVENTS**

# Speakers

## Introduction and Conclusions

### **Mary Clark**

Founder & CEO

Optimum Strategic Communications



Mary has a 25-year successful track record in providing strategic corporate and financial communications to both early- and late-stage healthcare companies and has worked with over 400 biotech and healthcare clients across Europe and the US. She has developed several high-profile investor focused campaigns and has been instrumental in strategic positioning ahead of fundraising rounds of private financings, IPOs and follow-on public financings. She founded Optimum in 2017 with the mission to provide the best strategic communications advice and implement effective communications programmes to achieve high impact results.


Prior to this, Mary built and led healthcare businesses at several international PR&IR agencies. She started her career at BTG plc where she was involved in the Company's IPO and the start-up of several new tech and biotech companies.

[Back to contents](#)



## **Hakan Goker**

Managing Director  
M Ventures



Hakan Goker, PhD, heads the Biotechnology Investments covering Healthcare and Life Sciences. He joined M Ventures in 2013 and has been investing in the sector for 18 years.

Previously, Hakan was a partner at Aescap Venture investing in European opportunities. Hakan started his investment career at Atlas Venture focusing on global investment opportunities in healthcare and medical technologies across US, Europe and Asia. He was instrumental in the creation and financing, business and R&D strategies of multiple companies while at Aescap and Atlas.

Hakan continues his active investing role and represents M Ventures on multiple portfolio companies. He comes from an academic background receiving his Ph.D. in oncology from the Institute of Cancer Research/ University of London, UK and continuing his scientific career with post-doctoral work at the Breakthrough Breast Cancer Centre/Royal Marsden Hospital. He gained his B.Sc. Hons, from University College London.




## **Mattias Johansson**

CEO , Ezenze and Founder  
Anglonordic Life Science Conference



Mattias Johansson founded the Anglonordic Life Science Conference in 2004 to facilitate and encourage communication across the investor and R&D communities of the UK and Scandinavia. He has over 20 years' experience in the Life Science industry with focus on partnering and investment.

Today Mattias is Director and Founder of Ezenze, a management consultancy in Sweden, with a focus on marketing and sponsorship management.



## Keynote

### **Dr. Laura Matz**

Chief Science and Technology Officer  
Merck KGaA, Darmstadt


Dr. Laura Matz is the Chief Science and Technology Officer at Merck, where she drives innovation and digitalization across Life Sciences, Healthcare, and Electronics.



As Executive Vice President, she oversees corporate innovation teams, including new business models. Until early 2025, Laura was also the CEO of Athinia®, a data-sharing platform that enables secure data sharing within the semiconductor ecosystem.

Prior to this, she was a Senior Vice President at EMD Electronics (formerly Versum Materials and Air Products Electronics division). She has been a key contributor to semiconductor materials growth, driving strong R&D to enable business success.

Laura champions science and engineering talent, building teams to address global challenges with innovation and rigor. She serves on the boards of SEMI Impact for Skills and AIChE. She holds a Ph.D. in Analytical Chemistry from Washington State University and a bachelor's from Indiana University of Pennsylvania.





# tranScrip

PRE-CLINICAL AND EARLY DEVELOPMENT

tranScrip is a **boutique drug development consultancy**, delivering **expert clinical, medical and regulatory solutions** to help transform **great science** into **valuable medicines**

-  Target Product Profile & Product Strategy
-  Translational Development Planning
-  IND / CTA Readiness & Gap Analysis
-  Early-Phase Trial Design & Execution
-  Clinical Development Strategy
-  CRO Selection & Oversight
-  Fractional Medical, Clinical & Regulatory Leadership

Lets Discuss Your Programme



[www.transcrip-group.com](http://www.transcrip-group.com)



[info@transcrip-group.com](mailto:info@transcrip-group.com)



## Panel: Ready, steady, Trial!

Novel approaches for better outcomes in clinical trials

---

### Chair: Charlotte Kremers


Principal

M Ventures

Charlotte is a Principal at M Ventures, having joined the team as a Fellow in September 2022. Charlotte received her BSc in Cell Biology, Physiology and Neuroscience from University College Utrecht and MSc in Neuroscience from University College London. She completed her PhD in Neuroscience at UCL, during which she investigated the pathomechanisms underlying a juvenile form of Amyotrophic Lateral Sclerosis.



Throughout her academic career, Charlotte was active in extracurricular activities, among others acting as a student biotech consultant, leading a sponsorship committee and organizing two conferences. She is based in Amsterdam at the M Ventures head office.



Panel: Ready, steady, Trial!

## David Apelian

Chief Executive Officer  
Theolytics



David is a physician/scientist and has held CMO and CEO positions in both the private and public company setting, including immune-oncology therapeutics companies.

David was the founding CEO of BlueSphere Bio, a startup arising from the University of Pittsburgh Medical Center, focused on creating personalized T-cell therapies for cancer, currently in clinical trials in patients with high-risk leukemia. He also served as CMO of Achillion Pharmaceuticals where he was responsible for its Hepatitis C portfolio clinical development strategy and managed the company's translational development programs for its complement factor D inhibitor (currently marketed as Voydeya for paroxysmal nocturnal hemoglobinuria). He also served as CMO of GlobelImmune, which focused on the development of therapeutic vaccines for the treatment of cancer and infectious diseases. Earlier in his career, David held clinical leadership positions at Bristol-Myers Squibb, and Schering Plough serving as the Medical Lead for the global registration of Baraclude in chronic hepatitis B, and the supplemental NDA submission for Rebetrone in pediatric patients with chronic hepatitis C. David received a BA and a PhD in Biochemistry from Rutgers University, an MD from the University of Medicine and Dentistry of New Jersey, and an MBA from Quinnipiac University.



Panel: Ready, steady, Trial!

## **Harel Kotler**

Clinical AI Lead  
Merck Healthcare



Harel is the Clinical AI Lead at Merck Healthcare, focused on integrating AI into clinical development workflows. He is an MD and data scientist committed to translating the latest technological innovations into trustworthy, domain-specific tools for healthcare. Prior to joining Merck, Harel worked at the Istituto Oncologico Veneto developing AI solutions for breast and lung cancer care.

## **Orr Inbar**

Co-Founder & Chief Executive Officer  
QuantHealth



Orr is a healthcare entrepreneur, technology, and business leader. A past co-founder and Head of Data Science at Concert AI (formerly Precision Health AI) he has led various healthcare, data science, product, and research teams around the world. Orr holds an MA in Information Technology from Harvard University and a BSc in Biochemistry from the University of Massachusetts, Amherst.

[Back to contents](#)



Panel: Ready, steady, Trial!

## **Chris Floyd**

Head of Neuroscience  
tranScrip



Chris is Head of Neuroscience at tranScrip and an expert in translational medicine, clinical pharmacology, and early development.

Dual accredited in Internal Medicine and Clinical Pharmacology, he has led numerous first-in-human and early-phase studies.

Formerly Senior Director at GSK, Chris has broad experience across monoclonals, oligonucleotides, and small molecules, and supports clients in advancing molecules from research to clinical development.

[Back to contents](#)



## Investors Panel

Trends in European Life Science Investment

---

### **Chair: Stephen Hansen**

Director of BioPharma Intelligence  
BioCentury



Stephen is BioCentury's Director of BioPharma Intelligence in the U.K., where he serves as one of the company's primary points of contact with European companies and investors. Stephen has covered clinical development, corporate strategy and finance in Europe, the U.S. and China for BioCentury for over a decade and is a frequent contributor to BioCentury's quarterly Financial Markets Preview and annual Buyside View and European Finance reports. He holds B.A.s in Biology and History from Bethel University and an M.Phil. in History from Oxford University.



## Investors Panel

### Maina Bhaman

Partner


Sofinnova Partners



Maina is a Partner in the Sofinnova Partners Capital Strategy. She joined the firm in 2018, bringing an extensive network and a long track record as a successful healthcare investor. Prior to joining Sofinnova, she was director of healthcare investment at Touchstone Innovations (formerly Imperial Innovations) in London, where she led and co-led investments in the UK.

Before turning to investing, Maina worked in the R&D teams of several UK and US biotech companies, including Celltech, Oxford GlycoSciences, Chimeric Therapies and GeneMedicine. At Sofinnova, her current investments include Purespring Therapeutics, Sitryx Therapeutics, Mironid Ltd, Myricx Bio, Mediar Therapeutics, Enyo Pharma, and Nuage Therapeutics.

Maina holds a Bachelor's in Science degree from the University of Texas at Austin and an MBA from the Imperial Business School.



## Investors Panel

### **Roel Bulthuis**

Managing Partner  
Syncona



Roel is a Managing Partner at Syncona, where he manages the investment team and utilizes more than 20 years of life science venture capital, business development and investment banking experience to help Syncona deliver value through the investment cycle. He is a Board member of iOnctura and Anaveon. Roel joined Syncona from Inkef Capital, an Amsterdam-based venture capital firm focused on life science investments. As Managing Partner and head of healthcare, he led the firm's growth into a leading European healthcare VC platform. Before this he served as SVP and Managing Director of Merck KGaA's M Ventures for almost 10 years, where he played an instrumental role in creating the business and building it into a leading corporate venture capital fund. Prior to his time at M Ventures, Roel held senior positions in global business development at Merck Serono and was in the investment banking team at Fortis Bank. Roel holds a MSc in Biopharmaceutical Sciences from Leiden University, Netherlands and an MBA in Finance from the Helsinki School of Economics, Finland. Roel is a Kauffman fellow and a Level20 mentor and is highly driven by the development of next generation investor and entrepreneurial talent.



## Investors Panel

### **Lucy Edwardes Jones**

Life Sciences Investor  
BGF



Lucy is a life sciences investor at BGF, the most active equity investor in the UK and Ireland with a balance sheet of £2.5bn.

Lucy focuses on investments in the life sciences space, with a particular interest in drug discovery platforms.

Her main role is to source and execute new investments, as well as supporting a number of investee companies at board level (currently Maxion Therapeutics, ViaNautis, Theolytics, NanoSyrinx). Prior to BGF, Lucy spent five years in strategy consulting at CIL where she focused on the healthcare and pharma sectors.



## Investors Panel

### **Hakan Goker**

Managing Director  
M Ventures

Hakan is Managing Director of M Ventures and heads the Biotechnology investments covering Healthcare and Life Sciences. Hakan joined M Ventures in 2013 and has been investing in the sector for 15 years. Hakan continues his active investing role and represents M Ventures on multiple portfolio companies. He comes from an academic background receiving his PhD in oncology from the Institute of Cancer Research/ University of London, UK and continuing his scientific career with post-doctoral work at the Breakthrough Breast Cancer Centre/Royal Marsden Hospital. He gained his BSc Hons from University College London. Hakan is based in Amsterdam at the M Ventures head office.



## Investors Panel

### **Allan Marchington**

Managing Director, Head of Life  
Sciences  
ICG



Allan is the Head of Life Sciences at Intermediate Capital Group PLC (ICG), a FTSE 100 asset manager with over \$82Bn under management. The ICG life sciences team was recently announced as one of two recipients of the UK Government LIFTs initiative. Their strategy is focused on investing in life science companies developing medicines to treat diseases for which there are no, or limited treatment options available for patients. Allan has been a Life Science investor for the last 20 years. Prior to joining ICG, he was formerly a Founding Partner at Bridge Valley Ventures, prior to this he was at Apposite Capital, and Abingworth. Allan has also had several operational roles during his career and was Senior Vice President at Millennium Pharmaceuticals in Cambridge, Mass. Allan joined Millennium following their acquisition of the company he founded, Cambridge Discovery Chemistry, where he was CEO. Allan began his career working for seven years in R&D at Pfizer. Allan serves on the BVCA Pensions and Private Capital Expert Panel.



## Panel: Partnering with Big Pharma

---

### **Chair: Ashleigh Furlong**

Health Reporter

Bloomberg

Ashleigh covers health care and the pharmaceutical industry for Bloomberg News from London. Previously, she wrote about global health policy at POLITICO.




Partnering with Big Pharma

## **Adi Hoess**

Chief Executive Officer  
ViaNautis

Adi brings over two decades of experience in biotechnology, having previously served as CEO of Affimed, where he was instrumental in advancing immuno-oncology therapies and securing multiple industry partnerships. He has a strong track record in leading companies through clinical development to commercialisation, both in Europe and the US. His extensive network within the biotech and pharmaceutical sectors has been key in fostering collaborations and securing funding. A medical doctor with a PhD from the University of Munich, Adi has deep expertise in product development, regulatory approvals, and intellectual property management.



Partnering with Big Pharma

## **Colette Lipp**

Senior Director, Global Oncology  
and Immuno- Oncology Licensing  
and Business Development

Merck KGaA



Colette is a Senior Director of Global Business Development, Oncology and Immuno-Oncology at Merck KGaA, Darmstadt, Germany. As part of Merck KGaA's Business Development team, she is responsible for establishing new collaborations and executing transactions, specifically in the oncology and immuno- oncology space. During her career, she has led a variety of negotiations including in-licensing Jiangsu Hengrui Pharmaceutical's PARP1 inhibitor with option to their Claudin18.2 ADC and co-leading Abbisko Therapeutics' pimicotinib, as well as the repatriation of Bavencio (avelumab) from Pfizer to Merck KGaA. She has also led three targeted protein degradation transactions, with C4 Therapeutics, Amphista Therapeutics and Proxygen, allowing Merck KGaA to expand its presence in the protein degradation field. Colette holds a DPhil in Biochemistry from the University of Oxford, an MSc in Molecular and Biological Chemistry from Ecole Polytechnique Federale de Lausanne (EPFL), and BSc from the Australian National University.




Partnering with Big Pharma

## **Nicki Thompson**

Chief Executive Officer  
TRIMTECH Therapeutics



Nicki has over 25 years' experience in pharmaceutical and biotechnology R&D in a variety of senior scientific and commercial leadership roles. Nicki is CEO of Cambridge-based TRIMTECH Therapeutics (an MRC LMB/UK DRI spin-out), which focuses on a novel targeted protein degradation (TPD) approach to treat neurodegenerative diseases. She recently led TRIMTECH through its recent \$31M seed financing. She was also founding CEO of Amphista Therapeutics, steering Amphista through Series A and B funding rounds, raising ~\$150 million in funding and closing two pharma collaborations (deal value \$2.3Bn). Her previous roles include VP/Global Head of External Drug Discovery (Roche); Senior Director, Business Development (GSK). Nicki's Biotech experience includes Chair of Nanna Therapeutic's Board (acquired by Astellas Pharma), Chair of the Board of Camena Bioscience and Head of Drug Discovery at Syntaxin.




## Panel: If I knew then what I know today

---

### **Chair: Mike Ward**

Global Head of Thought Leadership  
Clarivate

Mike serves as Global Head of Thought Leadership at Decision Resources Group (DRG), part of Clarivate. As both a journalist and analyst, Mike has been writing, analyzing and commenting on the life sciences industry for more than 35 years. He has held editorial and content leadership roles at various publications and organizations across the industry. In 2010, he was named European Mediscience Commentator of the Year and has been on the shortlist on other occasions in the past decade. In 2018, he was 4th on Labiotech's list of "Biotech Leaders You Should Know in the UK's Golden Triangle".



If I Knew Then...

## **Olav Hellebø**

Chairman

Blue Cell Therapeutics




Olav is a seasoned executive who has worked for over 30 years in pharmaceutical companies and biotechs. He has significant fundraising experience, having raised more than \$200m during his career, while he has also struck licensing deals and research collaborations with major companies including AstraZeneca, Takeda, Fosun, and Alnylam. Besides chairing Blue Cell Therapeutics, he also serves as Chief Executive Officer of BerGenBio, a clinical-stage biopharmaceutical company developing drugs for aggressive diseases. From 2014 to 2022 he was Chief Executive Officer of ReNeuron, a clinical-stage company specialising in cell therapy for ophthalmic and neurology-related diseases; and from 2010 to 2013 he headed oncology-focused biotech Clavis Pharma.



If I Knew Then...


## Marguerite Hutchinson

Chief Business Officer  
STORM Therapeutics



Marguerite has over ten years' extensive experience in leading licensing agreements and collaborations with large, high profile healthcare companies as well as experience in legal and strategic operations. She was previously the Chief Operating Officer and General Counsel of Plexikon Inc., a member of the Daiichi Sankyo Group, establishing and managing collaborations with Roche, Merck, AstraZeneca, Array and Cancer Research UK. She played a pivotal role in the out-licensing of bezuclastinib to Cogent Biosciences and plixorafenib to Fore Biotherapeutics, securing upfront payments and additional developmental milestones, and royalty payments. She was instrumental in the Phase 3 development and approval of TURALIO® (pexidartinib), a prescription medicine which is the first and only oral therapy for tenosynovial giant cell tumor. In addition, Marguerite successfully pursued the patent infringement case Plexikon v. Novartis, resulting in a significant jury verdict award and ongoing royalties from dabrafenib sales. Marguerite joined STORM from Tataro Therapeutics, where she was Chief Executive Officer, a UCSF spin-out which she set up and raised seed financing. Prior to this, Marguerite was Chief Business Officer at Frontier Medicines Corporation where she oversaw and led all business development activities including a collaboration with AbbVie. Marguerite received a B.A. from Harvard University and a J.D. from the University of San Diego School of Law and is based in US.

[Back to contents](#)



If I Knew Then...

## **Tara Raveendran**

Head of Healthcare Research  
Polar Capital


Tara joined Polar Capital in September 2021, as a consultant focused on independent research for the team. Prior to joining Polar Capital, she was the Head of Healthcare & Life Sciences Research at Shore Capital. Previously Tara spent over 15 years working in equity research, specializing in European pharmaceuticals, biotechnology and medtech at Lehman Brothers and Jefferies. She has also worked with a number of healthcare-focused startups through her life sciences consultancy, SSquared Consulting, most recently working with the UK government's Vaccine Taskforce.



## **Leopoldo Zambeletti**

Independent Director

Since 2013 Leopoldo has been an independent strategic advisor to life science companies on Merger and Acquisitions, out-licensing deals and financing strategy. He is a Non-Executive Director of Nogra Pharma, Philogen, Touchlight, LenioBio, Avanzanite and Senior Advisor to Mediobanca for HealthcareOrr is a healthcare entrepreneur, technology, and business leader. A past co-founder and Head of Data Science at Concert AI (formerly Precision Health AI) he has led various healthcare, data science, product, and research teams around the world. Orr holds an MA in Information Technology from Harvard University and a BSc in Biochemistry from the University of Massachusetts, Amherst.




# Charity of the Year: Barts Charity

---

**Jay Longworth**


Director of Fundraising & Communications



# Breakthroughs happen with Cooley

Advancing life sciences through unrivaled  
experience and industry relationships

With Cooley as your catalyst, you're not just part  
of the life sciences industry – you're shaping it.



# Technology Room Pitches

Morning

## Discovery Engines, AI & Drug Discovery Platforms

Chaired By: Davide Vacondio, M Ventures

---



### **Birgit Zech**

CEO

Anavo Therapeutics BV



Anavo Therapeutics is at the forefront of phosphatase-based drug discovery with its IGNITE platform, a unique approach for accessing a space previously considered undruggable. Based on its world-leading expertise in phosphatase-driven disease biology and drug discovery, the Company will unlock the full therapeutic potential of phosphatase-targeted allosteric modulators for its first-in-class proprietary pipeline in autoimmune disease, metabolism and cancer. Anavo is backed by blue-chip investors M Ventures, INKEF Capital, Taiho Ventures, MRL Ventures Fund, and Bioqube Ventures.

[Back to contents](#)



Discovery Engines, AI & Drug Discovery Platforms



## Irina Babina

CEO

Concr



Concr is a Deeptech astrophysics-rooted company providing digital twin simulations for precision oncology. Its mission is to turn complex molecular and clinical data into clear predictions of therapeutic response and outcome for every patient.



## Cora Griffin

Head of BD

Curve Therapeutics



Curve is an innovative biotech that has developed a pioneering, high-throughput, intracellular discovery platform. Its proprietary technology works to identify functional hits by pooled-screening of a gene-encoded Microcycle® library inside live mammalian cells. The Company is using this unique platform to build a strong pipeline of first-in-class macrocycle-derived drugs, with a focus on high-priority cancer, immunology and inflammation targets.

[Back to contents](#)



Discovery Engines, AI & Drug Discovery Platforms



## Martina Lubrano di Ricco

Chief of Staff

DeepLife




DeepLife is a techbio company advancing drug positioning through artificial intelligence and digital twins of human cell types. Its platform maps cell-type-specific regulatory networks by integrating over 100 million harmonized single-cell omics data points, enabling more precise target identification and disease understanding.

DeepLife applies this technology to its internal drug positioning pipeline in autoimmune and neurodegenerative diseases, and collaborates with pharmaceutical and biotech partners on target identification, asset de-risking, indication expansion, and disease relevance assessment.

[Back to contents](#)



Discovery Engines, AI & Drug Discovery Platforms



## Rod Chalk

Co-Founder & CEO


ionSIGHT



ionSIGHT develops machine learning software to enable high throughput drug screening using scalable native mass spectrometry. Its mission is to enable better drug discovery. The Company is a tech spinout from Oxford University and it is targeting the global £16Bn Pharma, Biotech and CRO markets for high throughput screening and surface plasmon resonance.

To date ionSIGHT has raised £250k, and is seeing follow-on investment towards its £1M seed round target to complete its SW development team. The Company is also seeking commercial partners engaged in drug discovery to work together with proof of concept, benchmarking and data sharing.

[Back to contents](#)



Discovery Engines, AI & Drug Discovery Platforms



## James Field

CEO

LabGenius Therapeutics



LabGenius Therapeutics is a drug discovery company at the forefront of discovering next-generation therapeutic antibodies. Its proprietary discovery platform, EVA™, combines advanced technologies from artificial intelligence, robotic automation, and synthetic biology to accelerate the discovery of novel multispecific antibodies.

Using EVA™, LabGenius generated its lead programme, LGTX-101, a highly selective and potent trivalent VHH-based Nectin-4 x CD3 T-cell engager.

LabGenius operates a hybrid business model that includes partnering with biotech and pharmaceutical companies in parallel with pursuing a wholly-owned therapeutic pipeline.

[Back to contents](#)



Discovery Engines, AI & Drug Discovery Platforms



## Morten Graugaard

CEO

Orbis Medicines



Orbis' broad pipeline is initially focused on delivering oral macrocycle candidates against targets validated by blockbuster biologic drugs. nCycles are the result of Orbis' systematic approach to macrocycle space exploration.

An nCycle is a macrocycle compound created by the Company's nGen platform.

Optimized for oral bioavailability and membrane permeability through a variety of parameters including a more modest size, nCycles are designed to deliver on the long-awaited promise of oral macrocycle drugs.

[Back to contents](#)



# Biotech Room 1 Pitches

Morning

## Oncology Therapeutics & Precision Cancer Approaches

Chaired By: Charlotte Kremers, M Ventures

---



### Susan Hill

CEO

Mestag Therapeutics



Mestag harnesses new insights into fibroblast-immune interactions to develop impactful treatments for patients with cancer and inflammatory diseases. The Company is progressing a pipeline of sophisticated first-in-class antibodies designed to direct and drive the immune system using known and emerging fibroblast-immune biology for a distinctly differentiated class of therapeutics. Its pipeline comprises the MST-0312 program, a FAP-LTBR bispecific agonist to conditionally induce tertiary lymphoid structures in solid tumors currently in preclinical development. Its second program, is a checkpoint agonist, targeting an immune checkpoint for the treatment of autoimmune and inflammatory disease. Separately, the Company is also identifying novel targets for future therapies through the application of its proprietary RAFT Platform.

[Back to contents](#)



## Oncology Therapeutics & Precision Cancer Approaches



### **Cosimo Ducani**

Co-Founder & CEO

Moligo Technologies



Moligo Technologies is a revenue generating DNA synthesis company producing non-viral DNA vectors over 10,000 bases, at industrial scale, with extremely high accuracy, and no sequence complexity limitations.

Today, Moligo is working with nearly 30 leading CGT and vaccine companies from the US, helping them develop safer and 200x cheaper therapies.



### **Sushanth Shetty**

CEO

OncoAssign



OncoAssign is an Institute of Cancer Research spin-out developing an RNA-based, AI-powered diagnostic platform to radically improve treatment prediction accuracy in various cancers.

[Back to contents](#)



## Oncology Therapeutics & Precision Cancer Approaches



**Ramzi Amri**

CEO

Oncoinvent




Oncoinvent is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. The lead product candidate, Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting micro-metastases post-surgery, harnessing the benefits of modern radiopharmaceuticals without the complexities of biological targeting.

Oncoinvent is investigating the safety and efficacy of Radspherin® in a clinical development program in two indications. One Phase 1 trial and one Phase 1/2a trial have been completed and one randomized Phase 2 trial is currently ongoing in the US and Europe.

Early clinical efficacy data are highly encouraging, and no serious toxicity or safety concerns have been reported to date. Oncoinvent is listed on the Oslo Stock Exchange (ONCIN).

[Back to contents](#)



## Oncology Therapeutics & Precision Cancer Approaches



### **Eloi Monreal**

Co-Founder & CEO

Business Development Manager



Oniria Therapeutics is a preclinical stage biopharmaceutical company in the field of precision oncology and focused on cancer persistence. ONR-688, its flagship product has already demonstrated efficacy in standalone conditions in CRC, AML and Melanoma, with excellent tolerability in rodents and non-rodent species.



### **Tony Johnson**

CEO and Chairman

Outrun Therapeutics



Outrun Therapeutics is pioneering protein stabilising therapeutics to treat major unmet medical needs with an initial focus on HPV-driven head and neck cancer. Outrun's technology involves engineering an E2 ligase modification to enable trapping of specific E3 ligases. This technology directly measures E3 ligase activity and allows for the first time to discover potent and selective E3 ligase inhibitors.

[Back to contents](#)



## Oncology Therapeutics & Precision Cancer Approaches



**Roy Pettipher**


CSO

Promatix Biosciences



Promatix Biosciences is a biotech company focused on the development of novel bispecific antibody drug conjugates for the treatment of cancer. The Company is using its proprietary proteomics database to identify pairs of receptor antigens to promote more selective tumour targeting and improved therapeutic efficacy.

[Back to contents](#)



# Biotech Room 2 Pitches

Morning

## Neuro, CNS & Brain-Linked Disorders

Chaired By: Nick Bastin, Optimum Strategic Communications

---



**Jordi Fabrega**

CEO

CONNECTA Therapeutics



CONNECTA Therapeutics is a clinical stage biotechnology company, based in Barcelona, discovering and developing innovative treatments for unmet CNS medical needs associated with neuroplasticity dysfunction.

Neuroplasticity plays a key role in human cognition and behavioural abilities and is affected in neurodevelopmental disorders such as Fragile X syndrome (FXS), Rett syndrome, Down syndrome, Autism Spectrum Disorder (ASD), Attention-deficit/hyperactivity disorder (ADHD), and the like, severely impacting the quality of life from the paediatric ages.

[Back to contents](#)



Neuro, CNS & Brain-Linked Disorders



**Dirk Beher**

CEO

FundaMental Pharma



FundaMental Pharma is a preclinical, seed stage biopharmaceutical company dedicated to removing barriers in treatment-resistant depression. Founded as a spin-off from the University of Heidelberg, FundaMental Pharma has established its independent operations at BioLabs in Heidelberg since 2023.

Built on the seminal work from Prof. Hilmar Bading and Dr. Jing Yan published in Science (Yan et al. 2020), its research team has recently discovered that its dual-acting modulators of the N-methyl-D-aspartate receptor (NMDAR) have the potential to redefine the current standard of care for treatment-resistant depression.

[Back to contents](#)



Neuro, CNS & Brain-Linked Disorders

## Nepsone

### Morten Fjordholt

CDO

Nepsone Pharma

Nepsone Pharma is a preclinical-stage biotech company developing drugs for dermatological diseases driven by imbalances in the autonomic nervous system rather than traditional immune-only mechanisms. Its lead program targets psoriasis first, with a broader pipeline vision that includes other inflammatory and autoimmune skin conditions such as eczema, alopecia areata and wound healing.



## POTENTIA

### Barak Azmon

Co-Founder & CEO

Potentia Ltd

Potentia Therapeutics is a private biotechnology startup developing targeted delivery platforms for RNA-based therapies, with a focus on antibody-oligonucleotide conjugates (AOCs) to enable precise modulation of gene expression in Schwann cells. The company's lead programmes aim to address peripheral nerve diseases, including CMT1A, with scalable and translatable delivery solutions.



[Back to contents](#)



Neuro, CNS & Brain-Linked Disorders



## Simon Kerry

CEO

Sania Therapeutics



Sania Therapeutics is developing a new class of controllable gene therapies designed to treat neurological symptoms driven by dysfunctional neural circuits. The platform combines localized, low-dose AAV delivery that selectively targets specific neuronal subpopulations with patient-controlled activation, allowing precise modulation of hyperactive neurons, improving symptoms without adversely and permanently altering normal neural function.

Sania's initial therapeutic target is a motor circuit disorder: spasticity. its broader goal is to expand into additional motor and sensory indications where current treatment options are limited, invasive, or poorly tolerated.

The company is built on world-class science originating from University College London.

[Back to contents](#)



Neuro, CNS & Brain-Linked Disorders



## David Cavalla

Executive Chairman & Co-founder

Serenatis Bio

Serenatis Bio is a Cambridge-based neuroscience biotech developing three first-in-class small-molecule programs for obsessive-compulsive and related disorders (OCRDs). Each program targets a distinct and validated neurobiological mechanism within OCD circuitry: AMPA neuromodulation, glutamatergic tone via mGluR2, and dopamine regulation via COMT.



## Mohammad Arastoo

CEO

TauBioGenix

Pre-commercialisation vehicle developing hS1D12, a best-in-class immunotherapy that potently neutralises the pathogenic tau species that drive Alzheimer's disease and related tauopathies. hS1D12 has shown industry leading data in a preclinical mouse model of Alzheimer's disease. Cell-based assays have also shown it has therapeutic potential in other dementias, termed tauopathies, in which tau is heavily involved.



[Back to contents](#)



# Technology Room Pitches

Afternoon

## Cell, Gene, RNA & Advanced Delivery Modalities

Chaired By: Stephen Adams, Optimum Strategic Communications

---



**Ulrik Cordes**

CEO & Founder

Cbio



Cbio A/S is a clinical-stage biotech company developing next-generation T-cell therapies engineered to cure metastatic solid tumors. Its proprietary REVITA® T-cell therapy platform is specifically designed for patients who no longer respond to standard treatments, with a clear focus on overcoming the hostile, oxidative stress-rich tumor microenvironment.

The technology has shown broad potential across multiple solid tumors, including cervical, head and neck, lung, melanoma, and ovarian cancers, creating a strong foundation for a diversified pipeline and strategic collaborations.

[Back to contents](#)



Cell, Gene, RNA & Advanced Delivery Modalities



**Jonas Båtelson**

CEO

CuraCell



CuraCell is a clinical-stage European biotech company developing T-cell therapies to treat cancer. its proprietary T-cell enrichment platform, CytoPLY, enables durable tumor responses on cold (hard-to-treat) solid tumors. The disruptively efficient manufacturing process, enabled through CytoPLY, paves the way for broad patient access.

CuraCell is committed to bring durable life-saving treatments to patients diagnosed with terminal cancer.

[Back to contents](#)



Cell, Gene, RNA & Advanced Delivery Modalities



**Ned Wakeman**

CEO

Nanoptima



NanOptima Ltd is a late pre-clinical company whose technology, engineered and developed by ex-AZ senior pharma: NAAmatrix™, is a bioresorbable natural amino acid matrix delivering unmodified retinal biologics (aflibercept, bevacizumab), small molecules (TKIs, dex), and peptides for up to six months from a standard intravitreal injection: no device, no implant, no curing, not kit, no training, no drug modification.

Unlike PLGA / synthetic depots or surgical implants, NAAmatrix™ biodegrades to amino acids, is pH-neutral, and fits existing clinic workflow unchanged.

Data: >6-month sustained in-vitro release with preserved bioactivity; clean 28-day in-vivo ocular tolerability. GB priority patent filed June 2025.

Raise: £1- £20m tranced through high value milestones through Phase I.

[Back to contents](#)



Cell, Gene, RNA & Advanced Delivery Modalities



## Tom Farrell

CEO

NanoSyrinx



NanoSyrinx is a discovery-stage synthetic biology company based in Coventry, UK, specialising in the intracellular delivery of protein therapeutics using its nano-scale, cell-specific delivery technology – the Nanosyringe™.

By advancing its platform technology, NanoSyrinx aims to revolutionise the treatment of complex diseases, providing new therapeutic possibilities where traditional methods have fallen short.

NanoSyrinx has secured ~\$25M in venture financing to date, backed by a prominent group of investors including M Ventures, BGF, Octopus Ventures, Eli Lilly and Company and Meltwind.

[Back to contents](#)



Cell, Gene, RNA & Advanced Delivery Modalities



**Anja Mølhart Høg**

EIR

smartRNA



smartRNA is developing a novel RNA therapeutics platform for targeted protein upregulation for treatment of monogenic disorders caused by decreased protein levels.

The platform functions by stabilizing the poly-A tail of mRNA which leads to increased translation of increased levels of the encoded protein.

The technology utilizes an endogenous universally expressed machinery and can be used across all cell types for targets where some functional mRNA is still present in the cell.

[Back to contents](#)



Cell, Gene, RNA & Advanced Delivery Modalities



## **Samantha Macro**

CFO

StemSight



StemSight develops off-the-shelf cell therapies for curing blindness. The Company's technologies build on a platform of gene-edited induced pluripotent stem cells (iPSCs) and clinical grade biomaterials for localized delivery of functional regenerative therapies.

StemSight showcases the technology in a high unmet need rare disease of the ocular surface, limbal stem cell deficiency (LSCD) and aims to expand into other therapeutic indications within ophthalmology and beyond.

StemSight is raising a €40M Series A to complete first-in-human studies in their lead indication and advance their pipeline.

[Back to contents](#)



Cell, Gene, RNA & Advanced Delivery Modalities



## Sam Barker

CBO

ViaNautis Bio




ViaNautis is transforming cell and gene therapy with polyNaut® nanovesicles (PNVs). Established as SomaServe as a UCL spin-out in 2018, the company now consists of an exceptional team of scientists and biotech leaders working from state-of-the-art facilities in Cambridge, UK.

ViaNautis is supported by blue chip investors including 4BIO Capital, BGF, UCB Ventures and Eli Lilly. Also backed by strategic partnerships with industry leaders, such as Eli Lilly and the Cystic Fibrosis Foundation, and validated by a board of sector pioneers, ViaNautis's pipeline spans high-impact programmes in CNS, cystic fibrosis, and immunology, and addresses patient populations from tens of thousands to millions.

[Back to contents](#)





# Driving innovation in healthcare and research

**For East London and beyond**



Find out more about Barts Charity and how you and your company can get involved. Scan the QR code or visit: [bartscharity.org.uk/philanthropy](https://bartscharity.org.uk/philanthropy)

# Biotech Room 1 Pitches

Afternoon

## Immunology, Inflammation & Systemic Disease

Chaired By: Emma Johnson, M Ventures

---



### Paul Little

CEO

Atrogi AB



Atrogi is a phase II ready Stockholm-based biotech company developing first-in-class, muscle-targeted oral  $\beta_2$ -adrenergic receptor modulators to transform treatment of obesity and metabolic disease. Its lead candidate, ATR-258, is a GRK-biased  $\beta_2$ -adrenergic receptor modulator that improves body composition by reducing fat while preserving lean muscle, with a differentiated cardiovascular safety profile supported by a recent Cell publication and Phase 1 data. Atrogi's muscle-centric strategy focuses on preserving and increasing lean mass and counteracting muscle loss from pharmacological weight-loss therapies and sarcopenia. Beyond ATR-258, Atrogi has a proprietary GPCR discovery platform of  $\beta_2$ -focused small molecules that supports a broader pipeline in muscle- and metabolism-related diseases

[Back to contents](#)



Immunology, Inflammation & Systemic Disease



## Guido Maertens

CFO

FcR Therapeutics



FcR Therapeutics is developing first-in-class antibody solutions for autoimmune disease.

Its proprietary drug leads can target Fc receptors to provide a major therapeutic perspective for patients suffering from various devastating autoimmune diseases.

[Back to contents](#)



Immunology, Inflammation & Systemic Disease



## Reuben Dawkins

Co-Founder & CEO


Link Biologics



Link Biologics is pioneering the development of protein biologics that harness the protective biology of TSG-6 and set new standards in multi-pathway modulation of inflammation and tissue protection and repair. With potential across multiple diseases, the Company's lead programmes focus on Dry Eye Disease (DED) and Wet Age-related Macular Degeneration (AMD), which together represent multi-billion-dollar global markets with significant unmet needs.

The Company's approach is validated by its DED programme (LB001), which has a fully funded >£200M partnership with Théa Group. Its Wet AMD programme (LB004), which utilises subcutaneous administration rather than intraocular injections, has been accelerated by leveraging data from LB001 alongside robust standalone preclinical data.

[Back to contents](#)



Immunology, Inflammation & Systemic Disease



**Nucleome**

THERAPEUTICS

## Mark Bodmer

CEO

Nucleome Therapeutics



A company tackling the molecular causes of inflammatory diseases through a breakthrough approach to 3D human genetics. Nucleome has identified molecular drivers of multiple inflammatory diseases by linking non-coding genetic variants to the genes they modify. Its lead program is an antibody targeting a key regulator of inflammation resolution.



**PharmaKrysto**

## Julian Howell

Founder

PharmaKrysto



PharmaKrysto was founded on the vision of saving kidneys and preventing pain in children and adults living with cystinuria. The Company's novel small molecules are orally bioavailable and prevent the formation of cystine stones - the cause of cystinuria.

[Back to contents](#)



# Biotech Room 2 Pitches

Afternoon

## Infectious Disease, Clinical Intervention & MedTech

Chaired By: Eva Haas, Optimum Strategic Communications

---



**Graeham Douglas**

Founder

AreteMedical



AreteMedical is developing the Respicorder, the world's first portable device integrating three clinical-grade lung measurements (spirometry, FeNO, and impulse oscillometry) in a single platform.

Like CGM for diabetes, the Company enables precision management of asthma and COPD through objective data rather than symptoms alone. Its patented technology uses proprietary sensor algorithms to achieve clinical-grade accuracy at lower cost and smaller size than competitors. Founded 2017, Cambridge UK.

[Back to contents](#)



Infectious Disease, Clinical Intervention & MedTech



## Helen Philippou

CEO

ClotProtect Therapeutics

ClotProtect is developing a first-in-class small molecule therapeutic approach to stop bleeding in patients at high risk or are bleeding, such as major surgery or a trauma incident. Its approach can address the unmet clinical needs of standard of care which is tranexamic acid (TXA), resulting in saving more lives from bleeding than TXA.



## Eran Zahavy

CEO

Cytonexa

Cytonexa is developing a novel non-invasive urine biopsy platform for monitoring patients with Non-Muscle Invasive Bladder Cancer.

The technology enables rapid, label-free analysis of urinary cells, aiming to replace frequent cystoscopy procedures with a simple urine test. The Company's platform combines advanced biophysical measurement and proprietary analytics to deliver accurate, cost-effective cancer monitoring suitable for routine clinical use.



[Back to contents](#)



Infectious Disease, Clinical Intervention & MedTech



## Elliot Bland

COO and Executive Director

iosBio



iosBio is revolutionising the \$12bn EBV market with OraPro-EBV, a first-in-class, oral, thermostable vaccine. Unlike injectable competitors, its proprietary "quad-layer" technology induces mucosal immunity (IgA) at the site of infection and systemic protection, offering a double barrier against the virus. With pre-clinical data demonstrating 52x higher potency than previous GSK attempts and a clear path to Phase 1b/2a, the Company addresses the massive unmet need for an EBV vaccine to prevent Multiple Sclerosis and associated cancers.



## George Frodsham

CEO

MediSieve



Developer of magnetic blood filtration platform, enabling removal of specific components directly from the bloodstream. Lead asset depletes AAV Neutralising antibodies, doubling patient eligibility for AAV gene therapies and potentially enabling redosing. Two active revenue generating partnerships.

[Back to contents](#)



Infectious Disease, Clinical Intervention & MedTech



MetalloBio<sup>TM</sup>

## Michael Murray

CEO

MetalloBio



MetalloBio is an antibacterials development company working on the first totally new classes of broad-spectrum, biofilm-busting antibiotic compounds to come out of R&D in over 50 years.

Arising from its proprietary inorganic chemistry platform are two classes of novel compounds, each with new modes of action and undetectable levels of onset of resistance.

KLS-1 Series molecules are positioned as new antibiotics. KLS-2 Series compounds are deployed in novel coatings and plastics with superior antibacterial performance compared to many commercialised products.

[Back to contents](#)



Infectious Disease, Clinical Intervention & MedTech



**Thomas Kledal**

CEO

Synklino




Synklino is a clinical stage biotechnology company pioneering transformative therapies for solid organ transplantation.

Its first-in-class breakthrough drug candidate, SYN002, is a therapeutic fusion protein designed to eliminate both active and latent CMV infection in donated organs through ex vivo organ perfusion, offering a proactive and life-changing therapy for immunocompromised transplant recipients.

Following regulatory approval, SYN002 is now entering clinical development in kidney transplantation.

[Back to contents](#)



# Delegations



**AseBio (Spanish Bioindustry Association)** brings together and represents the interests of companies, associations, foundations, universities and technology and research centres that work in the field of biotechnology in Spain.




[Back to contents](#)




# Delegations



Royal Danish Embassy, UK



[Back to contents](#)



# Delegations



We will create a better North East by connecting communities, giving people the skills to succeed and improving wellbeing for all. Collaborating with our partners we will make sure the North East is recognised as an outstanding place to live, work, visit and invest.



[Back to contents](#)



# ATTENDING INVESTORS

4BIO Capital  
A2E Industries  
Limited  
Aditum Bio  
Advent Life Sciences  
AION Labs  
AJYL  
Albion VC  
ALSA Ventures  
Angel Investor  
Angelini Ventures  
Apposite Capital LLP  
ARCH Venture  
Partners  
ARCHIMED Private  
Equity  
Astellas Venture  
Management  
Axilium Holding AB  
Biovision Ventures  
BlackRock  
BNP Paribas Asset  
Management

Brandon Capital  
British Business Bank  
Calculus Capital  
Caldwell Capital  
Cambridge  
Technology Capital  
Cancer Research  
Horizons, Ventures  
CGT Catapult Ventures  
Claret Capital Partners  
Consensus Business  
Group  
CPI Enterprises  
Deepbridge Capital  
Epidarex Capital  
Everquest Capital  
Evolutia Venture  
Partners  
Flerie Invest AB  
Forbion  
Foresight Group  
Future Planet Capital  
GL Capital

Gliding Ant Ventures  
Global Brain  
Gold Nest Capital &  
Synapto Ventures  
H Tree Capital  
Hermes Partners Intl.  
Ltd.  
HINA Bioventures  
Ignite Capital Partners,  
Inc  
Illumina Ventures  
Invest In Equity  
IPF Partners  
JJDC  
Kerna Ventures  
Kineo Finance  
London and Partners /  
MedCity  
Long River Investments

[Back to contents](#)



Longwall Venture Partners	Enterprises
M Ventures	Panacea Capital
Maudsley Enterprise	Panmure Liberum
Mazeation	Cambridge Capital
Meltwind	Parkinson's UK Virtual Biotech
Mid Atlantic Bio Angels	Peppermint
Momentum Biotech	VenturePartners
Monograph	Polar Capital
MSD	Rosetta Capital
New Science Fund	RYSE
NG Bio	SCI Ventures
NG Bio Ltd	Seventure
Nodenza Partners	Sofinnova
Nodenza Venture Partners	Sound Bioventures
Novateur Ventures Inc	SPRIM Global
o2h Ventures	Investments
Octopus Ventures	Sunstone Life Science
OMX Ventures	Ventures A/S
OrbiMed	Syncona Partners
Otsuka Pharmaceutical	The Pioneer Group
Oxford Science	UKI2S
	Vesalius Biocapital
	XGEN Venture SGR SpA
	Zinc

Correct at 21st April 2026

[Back to contents](#)





20th IPLS Annual Conference

Hosted by the Nordic PLG,  
join senior business development leaders in Stockholm for  
the IPLS 20th anniversary - an international partnering event  
designed to spark ideas, deals, and lasting relationships.

For over two decades, IPLS has been a trusted platform  
for deal-making and strategic connections, combining  
expert-led insights with structured meetings and  
valuable networking opportunities.

- NETWORKING IN THE NORDICS – WHERE DEALMAKERS CONNECT
- PARTNERING – DEDICATED PARTNERING SUPPORTED BY ONLINE PLATFORM
- DEVELOP – WHAT'S THE BIG DEAL? HEAR FRESH INSIGHTS, MARKET UPDATES AND PERSPECTIVES TO SUPPORT YOUR BUSINESS
- CONNECT – GROW YOUR INTERNATIONAL NETWORK
- PITCH – OPPORTUNITY TO SHOWCASE YOUR BUSINESS

international  
LIFE  
SCIENCE  
NETWORKING

# STOCKHOLM



[www.ipls.online](http://www.ipls.online)

**CIRIO**



# ATTENDING COMPANIES AND ORGANISATIONS

Alligator Bioscience	British Embassy Stockholm	FairJourney Bio
Analona Therapeutics	Business Region Göteborg	Famar
Anavo Therapeutics	CARBOGEN AMCIS	FcR Therapeutics
AreteMedical	CatSci	Flanders Investment & Trade
Arience Global	Cbio	FoRx Therapeutics
AstronauTx	Cima Universidad de Navarra	FreeMind Group
Asymchem	Clarivate	Freeths
Atelerix	Clinicology	FundaMental Pharma
Atrogi	ClotProtect Therapeutics	Genomics
Bart's Charity	Concr	GenProtex - University of Dundee
BGF	CONNECTA Therapeutics	GlobalData
BioCentury	Cooley (UK)	Grunenthal
BioPartner UK	CuraCell	ICG
BioSpace	Cure Parkinson's	Igaidi
Biotech Buddies	Curve Therapeutics	Indivior
BiotechTV	Cytonexa	InterSystems
BioWorld	DeepLife	Intract Pharma
BioXconomy	Dia Beta Labs	ionSIGHT analytics
Bloomberg	Dottikon Exclusive Synthesis	iosBio
Blue Cell Therapeutics	Embassy of Denmark	J A Kemp
BOOST Pharma	Evotec (UK)	Jiuzhou Pharma
Boyds	eXmoor Pharma	
Bristows	Ezenze Ltd	



Johnson & Johnson  
Kano Therapeutics  
Kesmalea Therapeutics  
Kriptonite  
Therapeutics  
Labcorp Drug  
Development  
Laboratories  
LabGenius Therapeutics  
London BioScience  
Innovation Centre  
Leitat  
LifeArc  
LightOx  
Link Biologics  
Lisa Urquhart  
Lonza  
Magnitude Biosciences  
Medicines Discovery  
Catapult  
Medicon Strategic  
Development  
MediSieve  
MEDiSTRAVA  
MedNous  
Merck Healthcare  
Merck KGAA  
Mestag Therapeutics

MetalloBio  
Microplate Dx  
Moligo Technologies  
NanOptima  
NanoSyrinx  
Nature Biotechnology  
Nepsone Pharma  
NoctuRNA  
Therapeutics  
Norstella  
Nucleome Therapeutics  
Olavide Neuron STX  
OncoAssign  
Oncoinvent  
ONIRIA THERAPEUTICS  
OPIS  
Optimum Strategic  
Communications  
Orbis Medicines  
Orikine Bio  
Osbot  
Outrun Therapeutics  
Pharma Holdings  
PharmaKrysto  
Pharmaron  
Potentia  
Promatix Biosciences  
Psyomics

QuantHealth  
Quintessence  
Rare Beacon  
Raymond James  
RDMCC  
ReproNovo  
Resolution  
Therapeutics  
Sania Therapeutics  
Sanner Group  
Selvita  
Senglobal  
Seqens  
Serenatis Bio  
smartRNA  
Solascure  
StemSight  
Stephenson Harwood  
STORM Therapeutics  
Supriya Mathur  
Sygnature Discovery  
Synklino  
TauBioGenix  
TECregen  
Tetraneuron  
THE GENOTYPE  
ADVISORY

[Back to contents](#)



The Science Behind  
Theolytics  
tranScrip  
TRIMTECH  
Therapeutics  
Twist Bioscience  
Upperton Pharma  
Solutions  
Vascversa  
Veranova  
Vernalis  
ViaNautis Bio  
Vitarka Therapeutics  
Viveca Biomed  
Weatherden  
WuXi AppTec  
WuXi Biologics  
Zelluna

Correct at 21st April 2026

[Back to contents](#)

